Rigel Pharmaceuticals | RIGL - Cash And Equivalent


Rigel Pharmaceuticals reported $48.53M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
Amgen USD 12.04B 2.91B Mar/2026
Anika Therapeutics USD 41.02M 16.46M Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celldex Therapeutics USD 28.87M 7.17M Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Ligand Pharmaceuticals USD 174.93M 489.59M Dec/2025
MacroGenics USD 57.22M 22.91M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 421M 218.49M Dec/2025
Veracyte USD 362.58M 47M Dec/2025